BOSTON, Nov. 14, 2025 /PRNewswire/ — Intrinsic Therapeutics, Inc., manufacturers of the Barricaid® bone-anchored annular closure device, announced today that Nick Nenadovich, MD, a board-certified orthopedic surgeon trained at the University of Chicago, completed the first endoscopic implantation of Barricaid in the Great Lakes region.
Dr. Nenadovich said, “Endoscopic approaches allow us to treat patients with less discomfort and facilitate a faster recovery. With the Barricaid implant, we can address not only current herniated discs, but also significantly decrease the risks of recurrent herniations. Coupled with an endoscopic approach, the Barricaid implant optimizes treatments and outcomes for patients with herniated discs.”
Endoscopic discectomies are one of the fastest growing procedures to treat herniated discs. Dr. Nenadovich used Amplify Surgical’s dualPortal® endoscopic approach which greatly reduces the learning curve and allows for faster integration of endoscopic procedures into a surgeon’s arsenal. The addition of Barricaid after a discectomy offers a significantly reduced risk of reherniation and provides longer-lasting relief from sciatic pain and the associated symptoms of a herniated disc compared to discectomy alone.
Greg Lambrecht, founder of Intrinsic Therapeutics, commented: “Surgeons across the country are learning that Barricaid maximizes and preserves outcomes in endoscopic discectomy cases. Incorporating Barricaid into a surgeon’s workflow for high-risk patients is quickly becoming the standard of care for discectomy patients.”
To view a video of Dr. Nenadovich’s procedure, follow the link: https://barricaid.com/first-endoscopic-barricaid-great-lakes/
About Barricade
Barricaid is a patented annular closure medical device designed to reduce re-operations for reherniations by 81%* in lumbar discectomy patients with large annular defects. Barricaid has been implanted in nearly 13,000 patients and is supported by clinical studies in eight different patient populations, including two randomized controlled trials and six single-arm studies. A level I multicenter RCT was published in JAMA demonstrating superior results to discectomy alone with five-year follow-up results. A new Category I CPT Code 63032 for bone-anchored annular closure will go into effect on January 1, 2026.
*Some studies are outside of FDA indications. Values at minimum 1 year postoperative. Minimum study size: 20 Barricaid subjects.
For complete benefit and risk information, visit www.Barricaid.com
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.
dualPortal is a registered trademark of Amplify Surgical, Inc.
CPT is a registered trademark of the American Medical Association (AMA).
SOURCE Intrinsic Therapeutics, Inc.
